Is a permanent flu vaccine on the cards?

If like me, you thought that the constantly evolving nature of the flu virus meant that annual vaccination was a fact of life for high-risk patients – maybe we should both think again.


When you consider it – flu jabs are an unusual thing.  Can you think of any other disease that requires an annual vaccination?  Some, like protection from tetanus bacteria, may not have permanent effects – but lasting 12 months? Surely we can do better then that!


Part of the problem lies with the ever-changing nature of the flu virus and part, in the outdated technology used in production of the vaccines themselves.


The key to the potential breakthrough is the discovery of a part of the virus that remains stable and could provide a constant target for the immune system.


Existing flu vaccines target a part of the vaccine that regularly mutates. This poses real problems for healthcare authorities who need to try and second guess which strain will become prevalent in a given period and lay in stocks accordingly.


Although this approach has undoubtedly saved lives, there are occasions when the authorities get it badly wrong. It is also a very expensive process, with annual flu jabs costing the US upwards of $3 billion!


The new vaccine has shown promising results in animals but they could mean that in a few years, annual vaccinations could be a thing of the past.



Share on LinkedIn


Share via Email


Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        Quintiles logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo                           
  • 21,183 STUDENTS
  • 9,400 COMPANIES